Standing Order
Amgen Inc.

Dashboard

Amgen Inc.

AMGNNASDAQ

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Universal block

Live market data + trailing fundamentals.

Market cap$236B
Price$435.6452w $271.18 – $478.48
Conviction5/ 5
Revenue (TTM)$38.9B
Revenue growth YoY+8.2%
P/E (trailing)25.1
Gross margin71.7%
Operating margin32.4%
Net margin24.1%
52w price change+51.0%
Next earnings—

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

  • Nov 9
    Ownership changeSEC

    SEC Form 4 insider transaction filing dated 2026-11-09.

  • Nov 9
    Ownership changeSEC

    SEC Form 4 insider transaction filing.

  • Nov 9
    Ownership changeSEC

    Form 4 filing reports change in Amgen insider beneficial ownership.

  • Nov 9
    Ownership changeSEC

    SEC Form 4 insider transaction filing.

  • Nov 3
    Financial resultsSEC

    Amgen files 8-K (items 2.02, 9.01) disclosing results of operations and financial condition.

  • Oct 27
    LeadershipSEC

    Amgen filed 8-K item 5.02 on director/officer departure, election or appointment.

  • Aug 13
    Ownership changeSEC

    Form 4 insider transaction filing.

  • Aug 12
    Ownership changeSEC

    SEC Form 4 insider transaction filing.

  • Aug 10
    Ownership changeSEC

    SEC Form 4 insider trading filing reported.

  • Aug 10
    Ownership changeSEC

    SEC Form 4 insider transaction filing.

  • Aug 10
    Ownership changeSEC

    SEC Form 4 insider transaction filing.

  • Aug 7
    Ownership changeSEC

    SEC Form 4 insider transaction filing for Amgen Inc.

  • Aug 7
    Ownership changeSEC

    SEC Form 4 insider transaction filing.

  • Aug 4
    Financial resultsSEC

    Amgen 8-K filed with items 2.02 and 9.01 on financial results.

  • Aug 4
    RegulatoryFDA

    FDA supplemental submission (SUPPL-210) for Neulasta (BLA125031) dated 2026-08-04.

  • Jul 31
    OtherSEC

    Amgen 8-K discloses material cybersecurity incident under Item 1.05.

  • Jul 16
    RegulatoryFDA

    FDA supplemental submission (SUPPL-5202) for NEUPOGEN (BLA103353) filed 2026-07-16.

  • Jun 23
    RegulatoryFDA

    FDA supplemental submission (SUPPL-224) for PROLIA (BLA125320) with status date 2026-06-23.

  • Jun 23
    RegulatoryFDA

    FDA supplemental submission (SUPPL-225) for PROLIA (BLA125320) filed 2026-06-23.

  • Jun 3
    Trial initiationClinicalTrials.gov

    Phase 1/2 TINI 2 trial (NCT05848687) for infant ALL recruiting

Not financial advice — research and opinion only. Disclosures